CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC
In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

Read more on News-Medical-Net